BeyondSpring, Inc. (BYSI) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, everyone, for joining today's call. I would like to advise listeners that comments made on today's call may reflect forward-looking statements that are related to such matters as BeyondSpring's clinical and preclinical research and development activities and results, regulatory and commercial plans, industry trends, market potential, collaborative initiatives, and financial projections, among others. While management believes that its assumptions, expectations, and projections are reasonable in view of the currently available information, you are cautioned not to place undue reliance on these forward-looking statements. The company's actual results may differ materially from those discussed during this call for a variety of reasons, including those described in the forward-looking statements and risk factors sections of the company's 20F and other filings with the SEC, which are available on the Investors section of BeyondSpring's website. Joining us on today's call is Dr. Fland Wong, BeyondSpring co-founder, chairman, and chief executive officer. Dr. Ramon Mojano, executive vice president, research and development, and chief medical officer. Richard Daly, chief operating officer. And Elizabeth Serpak, chief financial officer. It is now my pleasure to turn the call over to Dr. Lan Huang. Lan? Hello, everyone, and thank you for joining today's call. We're very pleased to be here today reporting our second quarter results and providing an update on the many meaningful events in the recent weeks. Everyone here at the company is very excited as we have accomplished so much But most importantly, we're most excited for patients who are our North Star, who can be helped by our lead asset, Penabalin. Penabalin is a first-in-class selective immunomodulating microtu...